NAFLD, Exercise, and Irisin: A Promising Signal, Not Proof

Exercise can help people with non-alcoholic fatty liver disease (NAFLD), but the popular story that muscles release irisin to calm a fatty liver runs ahead of the human evidence. In the only NAFLD randomized trial in this evidence base to measure irisin, a 12-week walking program did not raise irisin significantly more than nutrition education alone.

That does not weaken the case for exercise. NAFLD affects roughly one in four adults worldwide and ranges from simple fat accumulation in the liver to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It also travels with obesity, insulin resistance, and low activity. Structured exercise and dietary change can improve liver fat, inflammation, and cardiometabolic risk through several established pathways. Irisin may be part of that biology. It is not yet a proven therapeutic lever.

Why the muscle-to-liver idea is appealing

Irisin is a hormone-like peptide produced when the membrane protein FNDC5 is cleaved. The proposed sequence is tidy: exercise stimulates skeletal muscle, circulating irisin reaches the liver, and irisin dampens inflammatory signaling. Animal and cell experiments suggest that recombinant irisin can interfere with MD2, a component involved in TLR-4 signaling, suppress NF-kB activity, activate AMPK, and reduce new fat synthesis in liver cells.

The catch is scale and species. Those pathway experiments used cells or rodents and administered recombinant irisin at doses that typically exceed concentrations produced by human exercise by orders of magnitude. No human NAFLD trial has shown physiological exercise-induced irisin binding to liver cells, reduced hepatic NF-kB signaling, or reduced lipogenesis through this route. A plausible mechanism is a reason to run a better trial, not a substitute for one.

The direct human test produced a null comparison

Altay et al.'s 2024 randomized controlled trial enrolled 62 people with NAFLD and assigned them to nutrition education (15 participants), physical activity (16), combined nutrition education plus physical activity (14), or control care (16). The physical-activity program was moderate aerobic walking for 30 minutes per day, five days per week, over 12 weeks.

Irisin increased within each of the three intervention groups compared with the control group. Liver-enzyme trends for AST and ALT also fit a pattern of metabolic improvement. But the decision-relevant comparison was between groups: the study found no statistically significant differences among the groups for irisin, IL-6, TNF-alpha, or MD2. The walking arm did not show a significantly greater irisin increase than nutrition education alone, and adding walking to nutrition education did not establish an exercise-specific biomarker effect.

The nutrition-only result matters. If irisin rises when people receive nutrition education without a prescribed exercise intervention, then circulating irisin may reflect broader metabolic change rather than muscle contraction alone. Adiponectin-related signaling is one possible explanation, but the trial cannot identify the cause. It does, however, make the simple claim that exercise uniquely "switches on" irisin in people with NAFLD untenable.

A small study can miss an effect—and still cannot prove one

Each active group in Altay et al. contained only 14 to 16 participants. That leaves limited power for between-group biomarker comparisons, so a false-negative result is possible. The study cannot distinguish among three explanations: walking had no exercise-specific effect on irisin; the effect existed but the trial was too small to detect it; or measurement error obscured a real difference.

Measurement is a serious issue here. Human studies in this area have generally used commercial ELISA tests for circulating irisin. Questions remain about whether some kits measure authentic FNDC5/irisin peptide or cross-reactive fragments. Mass-spectrometry confirmation of peptide identity was absent from the human evidence discussed here. If the assay does not reliably measure the target molecule, a rise or fall in the reported value becomes hard to interpret.

The trial also assessed steatosis with ultrasound. Ultrasound can identify fatty liver but cannot precisely quantify modest changes in liver-fat fraction, especially below about 30% steatosis. MRI-PDFF would provide a continuous measure of liver fat, while biopsy can assess histology. Without those measures and without objective exercise monitoring such as accelerometry or continuous heart-rate data, the trial could not test whether a verified dose of exercise changed irisin and whether that change tracked a precise reduction in liver fat.

Exercise helps NAFLD without requiring an irisin explanation

The stronger practical conclusion is broader than one biomarker. A six-month lifestyle trial in NAFLD found that greater improvement in intrahepatic fat was associated with better oxidative-stress and inflammatory-marker profiles. It did not measure irisin, so it cannot show that irisin mediated those associations. It supports the more modest and useful idea that lowering liver fat often travels with improved inflammatory biology.

Exercise options also extend beyond walking. In an RCT of people with NASH, Keating et al. found high-intensity interval training safe, feasible, and cardiometabolically efficacious. The trial did not measure irisin, leaving the HIIT-to-irisin-to-liver pathway untested. A separate 2024 meta-analysis of 24 RCTs in sedentary adults found combined aerobic and resistance training improved glucose-metabolism and inflammatory markers. Those participants did not have confirmed NAFLD, but the results fit mechanisms already relevant to fatty liver: better insulin sensitivity and lower systemic inflammatory signaling.

Training may affect irisin, but the response is inconsistent. A 2024 systematic review and meta-analysis of randomized trials in overweight or obese adults found that circulating irisin responses to concurrent aerobic and resistance training varied substantially by training type, intensity, and duration. High heterogeneity prevented firm conclusions about the best modality. Because the review was not NAFLD-specific, it cannot tell patients with fatty liver how to train for an irisin increase.

Diet is not background scenery

Nutrition education deserves equal billing because dietary change can reduce liver steatosis independently of an irisin story. A 2023 systematic review of dietary strategies in NAFLD reported that Mediterranean-style diets, lower-carbohydrate approaches, and caloric restriction consistently reduced hepatic steatosis. The appropriate diet depends on the person, but the point is simple: changing food intake can improve the same metabolic terrain that exercise improves.

In NAFLD, a randomized trial of a low-glycemic-index Mediterranean diet plus aerobic activity also reported changes in gut-microbiota signatures. That is a reminder that the gut-liver axis, body weight, visceral fat, insulin sensitivity, diet quality, and exercise can all move together. A single blood biomarker rarely gets sole credit for a multi-organ intervention.

Irisin itself also changes outside exercise. In a randomized trial in people with type 2 diabetes, omega-3 fatty acids added to glimepiride improved irisin and SIRT-1 levels over 12 weeks. That study was not about NAFLD and cannot justify omega-3 as an irisin treatment for fatty liver. It does show why an irisin increase alone cannot establish a muscle-specific effect.

What to do with this evidence

Use exercise and dietary change to improve liver fat, fitness, insulin sensitivity, and cardiometabolic risk—not to chase an irisin number.

For someone with NAFLD, the studied walking prescription offers a concrete starting point: 30 minutes of moderate aerobic activity on five days each week. Resistance training or HIIT may suit some people, particularly when supervised and adjusted for fitness, symptoms, and medical conditions, but no NAFLD study has identified an irisin-maximizing protocol with proven liver benefits.

Pair training with a sustainable dietary pattern, often Mediterranean-style or low glycemic index when appropriate. Work with a clinician to assess fibrosis risk and monitor the condition; exercise is first-line care, not a replacement for evaluation when liver disease may be advancing.

The final verdict is pleasantly unglamorous. Exercise plus diet has evidence behind it. Irisin is an interesting candidate signal whose human measurement, specificity, and causal role remain unsettled. Any supplement or training plan claiming to boost irisin for liver health is asking you to buy the conclusion before the trials have earned it.